Aquestive Therapeutics Inc
AQST3.998USD
+0.178+4.66%
Horário de mercado （ET）Cotações atrasadas em 15 min
397.08MValor de mercado
PerdaP/L TTM
Mais detalhes de Aquestive Therapeutics Inc Empresa
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Informações da empresa
Código da empresaAQST
Nome da EmpresaAquestive Therapeutics Inc
Data de listagemJul 25, 2018
CEOMr. Daniel Barber
Número de funcionários142
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 25
Endereço30 Technology Dr
CidadeWARREN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal07059-5166
Telefone19089411900
Sitehttps://aquestive.com/
Código da empresaAQST
Data de listagemJul 25, 2018
CEOMr. Daniel Barber
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.85M
+33.44%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
313.57K
+24.59%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
303.11K
+27.67%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
293.84K
+26.99%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
156.86K
-1.70%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
75.08K
--
Dr. Marco Taglietti, M.D.
Dr. Marco Taglietti, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy E. Morris, CPA
Mr. Timothy E. Morris, CPA
Independent Director
Independent Director
--
--
Ms. Stephanie Carrington
Ms. Stephanie Carrington
Investor Relations
Investor Relations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.85M
+33.44%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
313.57K
+24.59%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
303.11K
+27.67%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
293.84K
+26.99%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
156.86K
-1.70%
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
5.20M
0.00%
Ex-United States
3.52M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 23 de mai
Atualizado em: sex, 23 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Crestline Investors, Inc.
9.88%
BlackRock Institutional Trust Company, N.A.
5.48%
The Vanguard Group, Inc.
4.10%
Perceptive Advisors LLC
3.75%
Armistice Capital LLC
2.77%
Other
74.02%
Investidores
Investidores
Proporção
Crestline Investors, Inc.
9.88%
BlackRock Institutional Trust Company, N.A.
5.48%
The Vanguard Group, Inc.
4.10%
Perceptive Advisors LLC
3.75%
Armistice Capital LLC
2.77%
Other
74.02%
Tipos de investidores
Investidores
Proporção
Investment Advisor
16.61%
Hedge Fund
16.46%
Individual Investor
6.00%
Investment Advisor/Hedge Fund
5.80%
Private Equity
5.10%
Research Firm
4.75%
Bank and Trust
0.10%
Venture Capital
0.08%
Pension Fund
0.02%
Other
45.09%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
267
54.56M
54.93%
-2.83M
2025Q1
270
54.42M
54.80%
-3.81M
2024Q4
246
52.68M
57.78%
-5.60M
2024Q3
235
56.04M
61.46%
+1.93M
2024Q2
197
48.34M
53.08%
-1.69M
2024Q1
166
46.95M
51.85%
+18.59M
2023Q4
129
27.01M
40.12%
+751.99K
2023Q3
131
26.75M
41.08%
+3.52M
2023Q2
143
22.79M
40.65%
+3.05M
2023Q1
161
18.71M
33.39%
-2.52M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Crestline Investors, Inc.
9.81M
9.88%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.44M
5.48%
-78.94K
-1.43%
Mar 31, 2025
The Vanguard Group, Inc.
4.07M
4.1%
-273.20K
-6.29%
Mar 31, 2025
Perceptive Advisors LLC
3.73M
3.75%
+3.73M
--
Mar 31, 2025
Armistice Capital LLC
2.75M
2.77%
+2.75M
--
Sep 30, 2024
Barber (Daniel)
1.85M
1.86%
+462.91K
+33.44%
Mar 21, 2025
Geode Capital Management, L.L.C.
1.70M
1.71%
+46.11K
+2.79%
Mar 31, 2025
State Street Global Advisors (US)
1.52M
1.53%
+18.76K
+1.25%
Mar 31, 2025
Pale Fire Capital SE
1.34M
1.34%
+809.93K
+154.05%
Mar 31, 2025
BofA Global Research (US)
1.33M
1.34%
+640.24K
+92.75%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.55%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.55%
iShares Micro-Cap ETF
Proporção0.06%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.03%
ProShares Hedge Replication ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
